Bird&Be Secures $13M Series A to Expand Fertility and Wellness Brand

Bird&Be Raises $13M Series A

Bird&Be, a Toronto-based fertility and wellness brand, has raised $13 million in Series A funding. The round was led by BFG Partners, with participation from Founder Collective, BDC Capital's Thrive Venture Fund, BAM Ventures, Rejuvenation Ventures, and HSR Ventures.

Company Background

Bird&Be was founded in 2021 by Samantha Diamond and Breanna Hughes after their own fertility struggles. The company sells doctor-formulated prenatal, pregnancy, postpartum, and hormone-support supplements, along with at-home fertility tests for both women and men.

Its product development combines reproductive-endocrinology and naturopathic expertise with third-party-tested ingredients.

Traction and Distribution

Bird&Be has grown into an eight-figure brand with nearly 100% year-over-year revenue growth. It sells through three main channels:

• Direct-to-consumer
• Nearly 1,000 Ulta Beauty doors
• A clinical distribution partnership with Mandell's Clinical Pharmacy

Why the Round Matters

The fertility and women's health category continues to attract investor attention, and Bird&Be's combination of clinical credibility, retail expansion, and DTC growth gives it a multi-channel footprint. The Series A provides capital to build on that momentum.

Deal Summary

• Company: Bird&Be
• Headquarters: Toronto, Canada
• Founded: 2021
• Founders: Samantha Diamond and Breanna Hughes
• Sector: Fertility and wellness
• Round: Series A
• Amount: $13 million
• Lead Investor: BFG Partners
• Participating Investors: Founder Collective, BDC Capital's Thrive Venture Fund, BAM Ventures, Rejuvenation Ventures, HSR Ventures
• Announced: September 22, 2026

What to Watch

With nearly 100% year-over-year growth and a presence in nearly 1,000 Ulta Beauty doors, Bird&Be is positioned to scale both its retail and clinical distribution. The Series A will likely support further product expansion and channel growth in the fertility and wellness market.